Fundz

Zetagen Therapeutics, Inc. reported raising $12.9 Million in an initial SEC Form D filing, from an offering of $1 Million

PRIVATEDec 26, 2018

Amount Raised

$12.9 Million

$12.9 Million sold, per SEC Form D (first sale Dec 26, 2018)

Round Type

Venture

SyracuseBiotechnologyHealthcareHealth Care

Who else raised in Healthcare and Biotechnology around the same time

Companies in the same sectors as Zetagen Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Monogram Health raised $5M (Seed) on February 7, 2019.
  • Microbot Medical raised $31K on February 5, 2019.
  • Tellus Therapeutics raised $75K (Pre-Seed) on January 31, 2019.
  • SPR Therapeutics raised $8M on January 30, 2019.
  • Purple Biotech raised $6M on January 24, 2019.
  • Monteris Medical raised $11M on January 22, 2019.

Who to call at Zetagen Therapeutics, and when

A new round usually means Zetagen Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Zetagen Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Zetagen Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Zetagen Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Zetagen Therapeutics

Location

841 EAST FAYETTE STREET

Syracuse, New York, United States

About

Zetagen is a private, clinical-stage biopharmaceutical company founded in 2015, focused on pioneering treatments for metastatic bone cancers and osteologic interventions. Its multi-patented ZetaMet™ technology, licensed exclusively from the State University of New York in 2016, is a first-of-its-kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. Zetagen’s drug-eluting implant therapy has successfully completed preclinical trials and is preparing for its first human clinical trial. The company’s pipeline also includes additional oncologic treatments for Skeletal Related Events (SREs), such as ZetaMet Flowable™, along with osteologic solutions including ZetaFuse™, ZetaSet™, ZetaDent™, and ZetaBase™, supported by Series A funding, private and angel investors, and NIH Phase I and II research grants.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Zetagen Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

3 contacts
Verified contactsBryan M., Chief Scientific Officer and Co-founder hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Zetagen Therapeutics's next move

See what Strategic adds

Zetagen Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.